RU2009108289A - Комбинированная терапия - Google Patents
Комбинированная терапия Download PDFInfo
- Publication number
- RU2009108289A RU2009108289A RU2009108289/15A RU2009108289A RU2009108289A RU 2009108289 A RU2009108289 A RU 2009108289A RU 2009108289/15 A RU2009108289/15 A RU 2009108289/15A RU 2009108289 A RU2009108289 A RU 2009108289A RU 2009108289 A RU2009108289 A RU 2009108289A
- Authority
- RU
- Russia
- Prior art keywords
- cxcr4 inhibitor
- pharmaceutically acceptable
- cxcr2 agonist
- csf
- acceptable salt
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims abstract 16
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims abstract 16
- 239000003112 inhibitor Substances 0.000 claims abstract 16
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims abstract 14
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims abstract 14
- 239000000556 agonist Substances 0.000 claims abstract 14
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims abstract 9
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 210000000130 stem cell Anatomy 0.000 claims abstract 8
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 claims abstract 7
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 claims abstract 7
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 claims abstract 7
- 229960002169 plerixafor Drugs 0.000 claims abstract 7
- 210000004027 cell Anatomy 0.000 claims abstract 6
- 210000005259 peripheral blood Anatomy 0.000 claims abstract 6
- 239000011886 peripheral blood Substances 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims abstract 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 3
- 230000001483 mobilizing effect Effects 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- CWJJHESJXJQCJA-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical group C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CC=N1 CWJJHESJXJQCJA-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83640906P | 2006-08-07 | 2006-08-07 | |
| US60/836,409 | 2006-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009108289A true RU2009108289A (ru) | 2010-09-20 |
Family
ID=39033325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009108289/15A RU2009108289A (ru) | 2006-08-07 | 2007-08-07 | Комбинированная терапия |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100178271A1 (enExample) |
| EP (1) | EP2056853A1 (enExample) |
| JP (1) | JP2010507567A (enExample) |
| CN (1) | CN101500595A (enExample) |
| AR (1) | AR062271A1 (enExample) |
| AU (1) | AU2007281677A1 (enExample) |
| BR (1) | BRPI0715393A2 (enExample) |
| CA (1) | CA2659337A1 (enExample) |
| IL (1) | IL196559A0 (enExample) |
| MX (1) | MX2009001445A (enExample) |
| RU (1) | RU2009108289A (enExample) |
| WO (1) | WO2008019371A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG177959A1 (en) * | 2007-01-09 | 2012-02-28 | Cleveland Biolabs Inc | Methods for increasing and mobilizing hematopoietic stem cells |
| WO2009108360A2 (en) * | 2008-02-29 | 2009-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of post-radiation tumor growth |
| US10813917B2 (en) * | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
| EP2549992B1 (en) | 2010-03-23 | 2019-08-14 | The Johns Hopkins University | Methods of treatment using stem cell mobilizers |
| EP2384759A1 (en) | 2010-05-06 | 2011-11-09 | Suomen Punainen Risti Veripalvelu | Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells |
| US8546353B2 (en) | 2010-05-06 | 2013-10-01 | Glykos Finland Oy | Compounds and combinations |
| ES2370986B1 (es) * | 2010-06-08 | 2012-11-16 | Institut Quimic De Sarria Cets | Nuevos inhibidores de cxcr4 como agentes anti-vih |
| WO2012047339A2 (en) | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US9682078B2 (en) | 2011-03-18 | 2017-06-20 | University Of Virginia Patent Foundation | Compositions and methods for tissue engineering and cell based therapies |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US20150030561A1 (en) | 2011-05-16 | 2015-01-29 | Genzyme Corp. | Use of CXCR4 Antagonists |
| US9763980B2 (en) | 2011-06-16 | 2017-09-19 | Children's Medical Center Corporation | Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| KR20160023638A (ko) * | 2013-02-28 | 2016-03-03 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 줄기세포를 이동하기 위한 방법 및 조성물 |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| CA3026154A1 (en) | 2015-06-03 | 2016-12-08 | The University Of Queensland | Mobilizing agents and uses therefor |
| WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| CN110035702A (zh) * | 2016-10-24 | 2019-07-19 | 耶鲁大学 | 穿刺装置 |
| WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
| EP3703714A1 (en) | 2017-11-03 | 2020-09-09 | Roemer & Heigl GmbH | Extraction of stem cells from bone marrow niches |
| CN111712262A (zh) * | 2017-12-06 | 2020-09-25 | 美真达治疗公司 | 用于动员造血干细胞和祖细胞的给药方案 |
| US11260079B2 (en) | 2017-12-06 | 2022-03-01 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
| US10058573B1 (en) | 2017-12-06 | 2018-08-28 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem cells |
| EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| WO2022101359A1 (en) | 2020-11-12 | 2022-05-19 | Roemer & Heigl Gmbh | Reversible release of stem cells from bone marrow niches |
| WO2025224720A1 (en) | 2024-04-24 | 2025-10-30 | Biolinerx Ltd. | Methods of selecting treatment regimen against solid tumors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| US5021409A (en) * | 1989-12-21 | 1991-06-04 | Johnson Matthey Plc | Antiviral cyclic polyamines |
| US6001826A (en) * | 1989-12-21 | 1999-12-14 | Anormed, Inc. | Chemical compounds |
| GB9126677D0 (en) * | 1991-12-16 | 1992-02-12 | Johnson Matthey Plc | Improvements in chemical compounds |
| ES2210255T3 (es) * | 1993-06-08 | 2004-07-01 | Smithkline Beecham Corporation | Metodos para mejorar la actividad biologica de quimiocinas. |
| US6447766B1 (en) * | 1993-06-08 | 2002-09-10 | Smithkline Beecham Corporation | Method of mobilizing hematopoietic stem cells |
| DE4320478B4 (de) * | 1993-06-21 | 2007-11-15 | Robert Bosch Gmbh | Fahrstabilitätsregler |
| GB9400411D0 (en) * | 1994-01-11 | 1994-03-09 | Johnson Matthey Plc | Improvements in chemical compounds |
| GB9511357D0 (en) * | 1995-06-06 | 1995-08-02 | Johnson Matthey Plc | Improved antiviral compounds |
| US6506770B1 (en) * | 1996-06-06 | 2003-01-14 | Anormed, Inc. | Antiviral compounds |
| US6713052B1 (en) * | 1995-10-24 | 2004-03-30 | Human Genome Sciences, Inc. | Method of mobilizing stem cells with chemokine β-8 |
| US6365583B1 (en) * | 1999-02-02 | 2002-04-02 | Anormed, Inc. | Methods to enhance white blood cell count |
| US6750348B1 (en) * | 1999-03-24 | 2004-06-15 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| WO2001044229A1 (en) * | 1999-12-17 | 2001-06-21 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds |
| US6864265B2 (en) * | 2000-09-15 | 2005-03-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds |
| DK1317451T3 (da) * | 2000-09-15 | 2006-12-18 | Anormed Inc | Kemokinreceptorbindende heterocykliske forbindelser |
| MXPA03002772A (es) * | 2000-09-29 | 2003-07-28 | Anormed Inc | Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos. |
| US6853731B1 (en) * | 2000-09-30 | 2005-02-08 | Keen Personal Technologies, Inc. | Digital video recorder employing a unique ID to interlock with encrypted video programs stored on a storage device |
| EP1385865A4 (en) * | 2001-04-03 | 2005-05-25 | Applera Corp | ISOLATED HUMAN KINASEPROTEINS, NUCLEIC ACID MOLECULES CODING FOR HUMAN KINASEPROTEINS AND THEIR USES |
| JP5137288B2 (ja) * | 2001-07-31 | 2013-02-06 | アノーメッド インコーポレイティド | 前駆／幹細胞を動員する方法 |
| US7169750B2 (en) * | 2001-07-31 | 2007-01-30 | Anormed, Inc. | Methods to mobilize progenitor/stem cells |
| EP1451297A4 (en) * | 2001-12-07 | 2006-06-28 | Toolgen Inc | PHENOTYPIC SCANNING OF CHIMERIC PROTEINS |
| CA2520259A1 (en) * | 2003-04-11 | 2004-10-28 | Anormed Inc. | Cxcr4 chemokine receptor binding compounds |
| CA2517077C (en) * | 2003-04-22 | 2013-03-12 | Anormed Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
| WO2005059107A2 (en) * | 2003-12-11 | 2005-06-30 | Anormed Inc. | Chemokine receptor binding compounds |
-
2007
- 2007-08-07 MX MX2009001445A patent/MX2009001445A/es unknown
- 2007-08-07 BR BRPI0715393-7A patent/BRPI0715393A2/pt not_active Application Discontinuation
- 2007-08-07 AR ARP070103484A patent/AR062271A1/es unknown
- 2007-08-07 US US12/376,591 patent/US20100178271A1/en not_active Abandoned
- 2007-08-07 EP EP07813853A patent/EP2056853A1/en active Pending
- 2007-08-07 CN CNA2007800295078A patent/CN101500595A/zh active Pending
- 2007-08-07 RU RU2009108289/15A patent/RU2009108289A/ru not_active Application Discontinuation
- 2007-08-07 WO PCT/US2007/075376 patent/WO2008019371A1/en not_active Ceased
- 2007-08-07 AU AU2007281677A patent/AU2007281677A1/en not_active Abandoned
- 2007-08-07 CA CA002659337A patent/CA2659337A1/en not_active Abandoned
- 2007-08-07 JP JP2009523960A patent/JP2010507567A/ja not_active Withdrawn
-
2009
- 2009-01-15 IL IL196559A patent/IL196559A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010507567A (ja) | 2010-03-11 |
| WO2008019371A1 (en) | 2008-02-14 |
| AR062271A1 (es) | 2008-10-29 |
| US20100178271A1 (en) | 2010-07-15 |
| EP2056853A1 (en) | 2009-05-13 |
| BRPI0715393A2 (pt) | 2013-06-25 |
| AU2007281677A1 (en) | 2008-02-14 |
| CA2659337A1 (en) | 2008-02-14 |
| CN101500595A (zh) | 2009-08-05 |
| IL196559A0 (en) | 2011-08-01 |
| MX2009001445A (es) | 2009-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009107030A (ru) | Комбинированная терапия | |
| JP2009545620A5 (enExample) | ||
| JP2010507567A5 (enExample) | ||
| Pusic et al. | Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells | |
| Fruehauf et al. | It's moving day: factors affecting peripheral blood stem mobilization and strategies for improvement. | |
| Bessard et al. | High antitumor activity of RLI, an interleukin-15 (IL-15)–IL-15 receptor α fusion protein, in metastatic melanoma and colorectal cancer | |
| ES2851601T3 (es) | Métodos para mejorar la proliferación y actividad de los linfocitos citolíticos naturales | |
| BR112021021165A2 (pt) | Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos | |
| AR062271A1 (es) | Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre | |
| CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
| EA201890516A1 (ru) | Клинические композиции | |
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| RU2009100930A (ru) | Лекарственные средства для стимуляции роста гемопоэтических стволовых клеток | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| JP2012525393A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| NZ578928A (en) | Methods to increase mobility of hematopoietic stem cells by use of a lipopeptide compound and treatment of associated diseases | |
| Moog | Management strategies for poor peripheral blood stem cell mobilization | |
| JP2023012503A5 (enExample) | ||
| RU2006106228A (ru) | Фармацевтическая композиция, используемая для мобилизации стволовых клеток | |
| JP2012532624A5 (enExample) | ||
| MX2024014994A (es) | Macrociclos de indazol y su uso | |
| RU2008152746A (ru) | Лечение ишемических заболеваний с применением эритропоэтина | |
| RU2008151713A (ru) | Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении | |
| Jin et al. | Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100808 |